388 related articles for article (PubMed ID: 31900793)
1. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis.
Guo M; Gu J; Teng F; Chen J; Ma X; Chen Q; Pu Y; Jiang Z; Long Y; Xu Y
Endocrine; 2020 Feb; 67(2):294-304. PubMed ID: 31900793
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
[TBL] [Abstract][Full Text] [Related]
3. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
[TBL] [Abstract][Full Text] [Related]
9. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Dholariya S; Dutta S; Singh R; Parchwani D; Sonagra A; Kaliya M
Expert Opin Pharmacother; 2023; 24(18):2187-2198. PubMed ID: 37817422
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
Castellana M; Cignarelli A; Brescia F; Perrini S; Natalicchio A; Laviola L; Giorgino F
Sci Rep; 2019 Dec; 9(1):19351. PubMed ID: 31852920
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
[TBL] [Abstract][Full Text] [Related]
12. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Li WX; Gou JF; Tian JH; Yan X; Yang L
Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
[TBL] [Abstract][Full Text] [Related]
17. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies.
Cai Y; Shi W; Xu G
Expert Opin Drug Saf; 2020 Nov; 19(11):1497-1504. PubMed ID: 32881584
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
